{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:57:20Z","timestamp":1781049440738,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1245\/s10434-021-10910-5","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T14:26:14Z","timestamp":1634221574000},"page":"791-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience"],"prefix":"10.1245","volume":"29","author":[{"given":"Michael J.","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"DePalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke D.","family":"Rothermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Straker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Baecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma H. A.","family":"Stahlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Paul","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Mahrukh Hussnain","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amod A.","family":"Sarnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Delman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Collichio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"10910_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/978-3-030-05070-2_32","volume-title":"Cutaneous melanoma","author":"JF Thompson","year":"2020","unstructured":"Thompson JF, Mozzillo N, Ross MI, et al. Local melanoma recurrence, satellitosis, and in-transit metastasis: incidence, outcomes, and selection of treatment options. In: CM Balch, MB Atkins, C Garbe, et al., editors. Cutaneous melanoma. Cham: Springer; 2020. p. 867\u201394."},{"issue":"25","key":"10910_CR2","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol."},{"issue":"13","key":"10910_CR3","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","volume":"25","author":"MC Perez","year":"2018","unstructured":"Perez MC, Miura JT, Naqvi SMH, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann Surg Oncol. 2018;25(13):3960\u20135.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"10910_CR4","doi-asserted-by":"publisher","first-page":"MMT19","DOI":"10.2217\/mmt-2019-0012","volume":"6","author":"MC Perez","year":"2019","unstructured":"Perez MC, Zager JS, Amatruda T, et al. Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). Melanoma Manag. 2019;6(2):MMT19.","journal-title":"Melanoma Manag."},{"issue":"4","key":"10910_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","volume":"228","author":"RJ Louie","year":"2019","unstructured":"Louie RJ, Perez MC, Jajja MR, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228(4):644\u20139.","journal-title":"J Am Coll Surg."},{"issue":"4","key":"10910_CR6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/ijc.32172","volume":"145","author":"V Franke","year":"2019","unstructured":"Franke V, Berger DMS, Klop WMC, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB\/C-IVM1a). Int J Cancer. 2019;145(4):974\u20138.","journal-title":"Int J Cancer."},{"issue":"4","key":"10910_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","volume":"14","author":"RM Conry","year":"2018","unstructured":"Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839\u201346.","journal-title":"Hum Vaccin Immunother."},{"issue":"4","key":"10910_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292\u2013303.","journal-title":"Gene Ther."},{"issue":"6","key":"10910_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2217\/fon.10.66","volume":"6","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6(6):941\u20139.","journal-title":"Future Oncol."},{"key":"10910_CR10","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Cutaneous Melanoma version 3.2019. 2019."},{"issue":"4","key":"10910_CR11","first-page":"141","volume":"33","author":"MJ Mooradian","year":"2019","unstructured":"Mooradian MJ, Sullivan RJ. What to do when anti-PD-1 therapy fails in patients with melanoma. Oncology (Williston Park). 2019;33(4):141\u20138.","journal-title":"Oncology (Williston Park)."},{"issue":"6","key":"10910_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-1119.e1110.","journal-title":"Cell"},{"issue":"7","key":"10910_CR13","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1245\/s10434-018-6361-5","volume":"25","author":"F Collichio","year":"2018","unstructured":"Collichio F, Burke L, Proctor A, et al. Implementing a program of talimogene laherparepvec. Ann Surg Oncol. 2018;25(7):1828\u201335.","journal-title":"Ann Surg Oncol."},{"key":"10910_CR14","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/OTT.S133699","volume":"10","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, Michielin O, Malvehy J, et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 2017;10:3867\u201380.","journal-title":"Onco Targets Ther."},{"issue":"2","key":"10910_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-014-4072-0","volume":"22","author":"DJ Muilenburg","year":"2014","unstructured":"Muilenburg DJ, Beasley GM, Thompson ZJ, Lee J-H, Tyler DS, Zager JS. Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. 2014;22(2):482\u20138.","journal-title":"Ann Surg Oncol."},{"key":"10910_CR16","volume-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979."},{"issue":"22","key":"10910_CR17","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619\u201326.","journal-title":"J Clin Oncol."},{"issue":"17","key":"10910_CR18","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658\u201367.","journal-title":"J Clin Oncol."},{"key":"10910_CR19","unstructured":"Long GV, Dummer R, Andtbacka RH, et al. Follow-up analysis of MASTERKEY-265 phase 1b (ph1b) study of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (pembro) in patients (pts) with unresectable stage IIIB\u2013IVM1c melanoma (MEL). In: Society for Melanoma Research Fifteenth International Congress; October 24\u201327, 2018, 2018; Manchester, England."},{"issue":"1","key":"10910_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-018-0337-7","volume":"6","author":"L Sun","year":"2018","unstructured":"Sun L, Funchain P, Song JM, et al. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6(1):36.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"10910_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/CMR.0000000000000444","volume":"28","author":"J Chesney","year":"2018","unstructured":"Chesney J, Imbert-Fernandez Y, Telang S, et al. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Res. 2018;28(3):250\u20135.","journal-title":"Melanoma Res"},{"issue":"1","key":"10910_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CMR.0000000000000501","volume":"29","author":"T Seremet","year":"2019","unstructured":"Seremet T, Planken S, Schwarze JK, et al. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. Melanoma Res. 2019;29(1):85\u20138.","journal-title":"Melanoma Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10910-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:20:24Z","timestamp":1641223224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10910-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10910"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10910-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. has received research funding from Amgen. A.v.A. receives advisory board and consultancy honoraria from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Sanofi and 4SC, all paid to the institution. He has received research grants from Amgen, Bristol-Myers Squibb, and Novartis, all paid to the institution. F.C.\u2019s institution receives research funding from Amgen, Merck and Novartis, a portion of which supports her salary. J.S.Z. has advisory board relationships with Merck speaker\u2019s bureau for Pfizer and Sun Pharma. He also receives research funding from Amgen, Delcath Systems, Philogen, Provectus and Novartis. He also is a member of the speaker\u2019s bureau for Amgen and SunPharma. A.S.\u2014Consulting fees and sponsored travel from Iovance Biotherapeutics Inc. Consulting fees from Guidepoint and Defined Health Inc. Honorarium and sponsored travel from Physicians' Educational Resource, LLC. Patent royalties from methods to improve adoptive cell therapy using tumor-infiltrating lymphocytes. None of the financial disclosures are related to this present work. The remaining authors have no relevant conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}